Just a biotech and a Chinese issuer are expected to IPO in the week ahead as the market prepares for the February lull.
Early-stage oncology biotech Revolution Medicines (RVMD) is expected to raise $150 million at an $850 million market cap. Backed by Third Rock, the company's lead candidate (a collaboration with Sanofi) is an RAS pathway SHP2 inhibitor and is currently in a Phase 1/2 trial. Another early-stage oncology biotech targeting kinase inhibitors, recent IPO Black Diamond Therapeutics (BDTX) is currently up 106% as the hot streak for biotech IPOs continues.
Chinese online insurance marketplace Huize Holding (HUIZ) plans to raise $48 million at a $561 million market cap. The company is a licensed insurance intermediary and has served 6 milliom clients as of 9/30/19. Fewer than 10 outside investors have indicated intention to purchase up to $50 million worth of shares in the IPO (103% of the deal size).
Lock-up periods will be expiring for two companies and Street research is expected for four companies.
Track lock-ups and Street research dates on the IPO Pro Master Calendar.
|U.S. IPO Calendar|
|$9.40 - $11.40
|Operates an online insurance marketplace in China.|
|Revolution Medicines (RVMD)
Redwood City, CA
|$14 - $16
|Phase 1/2 biotech developing targeted cancer therapies using RAS pathway inhibitors.|
Sign up for a free trial of our premium platform, IPO Pro. Follow us on Twitter (@IPOtweet) and register for our updates on the IPO market.
The following IPOs are expected to price this week:
Revolution Medicines (RVMD), a Phase 1/2 biotech developing targeted cancer therapies using RAS pathway inhibitors, plans to raise $150 million by offering 10 million shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, Revolution Medicines would command a market value of $850 million. Revolution Medicines, which was founded in 2015, booked $48 million in sales over the last 12 months. The Redwood City, CA-based company plans to list on the Nasdaq under the symbol RVMD. J.P. Morgan is the lead bookrunner on the deal.
Huize Holding (HUIZ), which is a licensed insurance intermediary operating platform, plans to raise $48 million by offering 4.7 million ADSs at a price range of $9.40 to $11.40. At the midpoint of the proposed range, Huize Holding would command a market value of $561 million. The company is headquartered in Shenzhen, China and plans to list on the Nasdaq under the symbol HUIZ. Citi is the lead bookrunner on the deal.
Renaissance Capital will have Pre-IPO Research available on each of these upcoming IPOs prior to its pricing.
IPO Market Snapshot
The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/6/20, the Renaissance IPO Index was up 8.4% year-to-date, while the S&P 500 had a gain of 3.6%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber (UBER) and Spotify (SPOT). The Renaissance International IPO Index was up 4.4% year-to-date, while the ACWX was down 0.2%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Adyen and SoftBank.